Clinical Colorectal Cancer, Volume 19, June 2020,
Metastatic colorectal cancer outcomes continue to improve, but they vary significantly by race and ethnicity. Hypothesizing that these disparities arise from unequal access to care rather than intrinsic biology, we showed that survival of 103 consecutive patients with metastatic colorectal cancer treated at an academic safety-net hospital that treats the underserved, predominantly minority population of Harris County, Texas, was superior to that of subjects enrolled in the CRYSTAL (Cetuximab Combined with Irinotecan in First-Line Therapy for Metastatic Colorectal Cancer) trial. Our findings suggest that administering high-quality comprehensive cancer care to vulnerable populations can overcome disparities reported in the medical literature.
Academic Medical Centers; Adult; African American; African Americans; Aged; Article; Asian; Asian American; Asian Americans; Bevacizumab; Black; Black Person; Cancer Chemotherapy; Cancer Patient; Cancer Radiotherapy; Cancer Surgery; Cancer Survival; Capecitabine; Caucasian; Cetuximab; Clinical Pathway; Colorectal Neoplasms; Colorectal Tumor; Comparative Study; Disparities; Economics; European Continental Ancestry Group; Evidence Based Practice; Female; Financial Management; Fluoropyrimidine; Fluorouracil; Folinic Acid; Health Care Delivery; Health Care Disparity; Healthcare Disparities; Hispanic; Hispanic Americans; Human; Humans; Integration; Irinotecan; Kaplan Meier Method; Kaplan-Meier Estimate; Major Clinical Study; Male; Medically Uninsured; Metastatic Colorectal Cancer; Middle Aged; Middle East; Minority Group; Minority Groups; Mortality; Outcome Assessment; Overall Survival; Oxaliplatin; Panitumumab; Patient Acceptance Of Health Care; Patient Attitude; Randomized Controlled Trial (topic); Randomized Controlled Trials As Topic; Regorafenib; Retrospective Studies; Retrospective Study; Safety Net Health Care; Safety Net Hospital; Safety-net Providers; Socioeconomic Factors; Socioeconomics; Stage 4; Survival; Survival Rate; Treatment Response; Underserved; University Hospital; Vulnerable Population; Global